CHM.CN Stock Surges 900% in April 2026: Waverunner Capital Inc. High Volume Mover

Waverunner Capital Inc. (CHM.CN) has become a high volume mover on Canada’s CNQ exchange, with CHM.CN stock surging 900% from CAD 0.005 to CAD 0.05 in April 2026. This dramatic spike reflects extreme volatility in the venture capital firm’s shares. The company, formerly known as Chemistree Technology Inc., recently rebranded to focus on early-stage investments across renewable energy, biotechnology, and plant-based wellness sectors. With a market cap of CAD 37.21 million and 744.23 million shares outstanding, CHM.CN stock remains highly speculative. Investors should understand the risks before trading this volatile security.

CHM.CN Stock Price Action: 900% Surge Signals Extreme Volatility

CHM.CN stock has experienced a dramatic 900% price increase, moving from CAD 0.005 to CAD 0.05 in recent trading. This explosive move marks one of the most significant single-day rallies for Waverunner Capital Inc. on the CNQ exchange. The stock’s 50-day moving average sits at CAD 0.0424, while the 200-day average is CAD 0.0481, indicating the current price trades above both key technical levels.

The year-to-date performance shows CHM.CN stock has recovered from its 52-week low of CAD 0.05 but remains well below the 52-week high of CAD 0.10. Average daily volume of 28,908 shares suggests moderate liquidity despite the price surge. This high volume mover pattern indicates renewed investor interest in Waverunner Capital Inc., though traders should note the extreme volatility creates both opportunity and significant downside risk.

Waverunner Capital Inc. Business Model: Venture Capital Focus

Waverunner Capital Inc. operates as a venture capital firm specializing in early-stage investments and growth capital across multiple sectors. The company targets equity investments between CAD 500,000 and CAD 1 million, with enterprise values ranging from CAD 2 million to CAD 5 million. CHM.CN stock represents ownership in a diversified portfolio spanning renewable energy (wind and solar), plant-based wellness, and consumer-targeted biotechnology.

Based in North Vancouver, British Columbia, Waverunner Capital Inc. invests through both its own balance sheet and personal capital from management. The company seeks opportunities across Europe and North America, providing exposure to early-stage ventures. This business model creates both growth potential and significant risk, as early-stage investments frequently fail. Investors in CHM.CN stock should recognize they’re backing a venture capital strategy, not a traditional operating company.

Financial Metrics: Understanding CHM.CN Stock Fundamentals

CHM.CN stock presents challenging financial metrics that reflect the company’s venture capital nature and current losses. The earnings per share (EPS) stands at negative CAD 0.01, with a price-to-earnings ratio of -5.0, indicating unprofitability. Net income per share is negative CAD 0.0595, while operating cash flow per share is negative CAD 0.0044.

The current ratio of 0.097 signals potential liquidity concerns, as current assets barely cover current liabilities. Book value per share is negative at CAD 0.1422, suggesting shareholders’ equity is negative. However, Meyka AI rates CHM.CN stock with a score of 61.25 out of 100, assigning a B grade with a HOLD suggestion. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed, and we are not financial advisors.

Healthcare Sector Context: CHM.CN Stock in Perspective

Waverunner Capital Inc. operates within the Healthcare sector, classified under Drug Manufacturers – Specialty & Generic. The broader Healthcare sector on Canadian markets shows mixed performance, with an average P/E ratio of 16.09 and significant variation among constituents. CHM.CN stock’s negative earnings metrics contrast sharply with sector leaders like UnitedHealth Group and Thermo Fisher Scientific.

The Healthcare sector’s average net margin is negative 1,247.38%, heavily influenced by biotech and venture-backed companies like Waverunner Capital Inc. Sector performance over the past year shows -5.19% returns, indicating headwinds for healthcare investments. However, the sector’s focus on innovation and growth creates opportunities for venture capital firms backing emerging biotechnology and wellness companies. CHM.CN stock investors should monitor broader sector trends alongside company-specific developments.

Technical Analysis and Trading Signals for CHM.CN Stock

CHM.CN stock’s technical setup shows the price trading at resistance levels established by the 52-week high of CAD 0.10. The current price of CAD 0.05 represents a 50% pullback from that peak, suggesting potential consolidation. The 50-day moving average at CAD 0.0424 provides support below current levels, while the 200-day average at CAD 0.0481 offers additional technical support.

The extreme 900% price surge indicates strong buying pressure, though average volume of 28,908 shares remains modest for such a dramatic move. This pattern suggests retail investor interest or a significant catalyst driving the rally. Traders should watch for volume confirmation above 50,000 shares to validate the breakout. The stock’s high volatility creates both trading opportunities and substantial risk, making stop-loss orders essential for risk management.

Meyka AI Forecast and Investment Outlook for CHM.CN Stock

Meyka AI’s forecast model projects CHM.CN stock based on historical patterns, financial metrics, and market conditions. The current price of CAD 0.05 reflects the recent 900% surge from CAD 0.005. Forecasts are model-based projections and not guarantees of future performance. Given the company’s negative earnings and venture capital focus, price appreciation depends heavily on successful portfolio company exits and capital gains.

The venture capital model creates binary outcomes: successful exits drive significant returns, while failed investments result in losses. Meyka AI’s HOLD rating suggests waiting for clearer fundamental improvement before accumulating CHM.CN stock. Investors should monitor quarterly updates on portfolio performance, new investment announcements, and management commentary. The stock’s extreme volatility makes it suitable only for risk-tolerant traders with appropriate position sizing and stop-loss discipline.

Final Thoughts

CHM.CN stock has captured attention as a high volume mover with its dramatic 900% surge to CAD 0.05 on Canada’s CNQ exchange. Waverunner Capital Inc. represents a venture capital investment opportunity with exposure to renewable energy, biotechnology, and plant-based wellness sectors. However, the company’s negative earnings, weak balance sheet metrics, and speculative nature demand careful consideration. Meyka AI assigns CHM.CN stock a B grade with a HOLD recommendation, reflecting mixed fundamentals and significant uncertainty. The stock’s extreme volatility creates trading opportunities for experienced investors but poses substantial risk for conservative portfolios. Before investing in CHM.CN stock, conduct thorough due diligence on the company’s portfolio companies and management track record. Position sizing and stop-loss orders are essential risk management tools for this high-volatility security. Monitor quarterly earnings reports and portfolio updates for signs of fundamental improvement or deterioration.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.